731 related articles for article (PubMed ID: 28597939)
1. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
2. Integrating proteomics into precision oncology.
Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
[TBL] [Abstract][Full Text] [Related]
3. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
4. Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
Lier A; Penzel R; Heining C; Horak P; Fröhlich M; Uhrig S; Budczies J; Kirchner M; Volckmar AL; Hutter B; Kreutzfeldt S; Endris V; Richter D; Wolf S; Pfütze K; Neumann O; Buchhalter I; Morais de Oliveira CM; Singer S; Leichsenring J; Herpel E; Klauschen F; Jost PJ; Metzeler KH; Schulze-Osthoff K; Kopp HG; Kindler T; Rieke DT; Lamping M; Brandts C; Falkenhorst J; Bauer S; Schröck E; Folprecht G; Boerries M; von Bubnoff N; Weichert W; Brors B; Lichter P; von Kalle C; Schirmacher P; Glimm H; Fröhling S; Stenzinger A
JCO Precis Oncol; 2018 Nov; 2():1-13. PubMed ID: 35135162
[TBL] [Abstract][Full Text] [Related]
5. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
6. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
7. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
8. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
9. Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream.
Mack SC; Northcott PA
J Clin Oncol; 2017 Jul; 35(21):2346-2354. PubMed ID: 28640705
[TBL] [Abstract][Full Text] [Related]
10. Histological tumor typing in the age of molecular profiling.
Klauschen F; Heim D; Stenzinger A
Pathol Res Pract; 2015 Dec; 211(12):897-900. PubMed ID: 26589872
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
12. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Jahn A; Rump A; Widmann TJ; Heining C; Horak P; Hutter B; Paramasivam N; Uhrig S; Gieldon L; Drukewitz S; Kübler A; Bermudez M; Hackmann K; Porrmann J; Wagner J; Arlt M; Franke M; Fischer J; Kowalzyk Z; William D; Weth V; Oster S; Fröhlich M; Hüllein J; Valle González C; Kreutzfeldt S; Mock A; Heilig CE; Lipka DB; Möhrmann L; Hanf D; Oleś M; Teleanu V; Allgäuer M; Ruhnke L; Kutz O; Knurr A; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Metzeler KH; Bitzer M; Schulze-Osthoff K; von Kalle C; Brors B; Stenzinger A; Weichert W; Hübschmann D; Fröhling S; Glimm H; Schröck E; Klink B
Ann Oncol; 2022 Nov; 33(11):1186-1199. PubMed ID: 35988656
[TBL] [Abstract][Full Text] [Related]
14. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
Tripathy D; Harnden K; Blackwell K; Robson M
BMC Med; 2014 Aug; 12():140. PubMed ID: 25286031
[TBL] [Abstract][Full Text] [Related]
15. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
[TBL] [Abstract][Full Text] [Related]
16. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
17. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
18. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.
Nakamura Y; Fujisawa T; Taniguchi H; Bando H; Okamoto W; Tsuchihara K; Yoshino T; Ohtsu A
Cancer Sci; 2021 Nov; 112(11):4425-4432. PubMed ID: 34510657
[TBL] [Abstract][Full Text] [Related]
19. The Personalization of Therapy: Molecular Profiling Technologies and Their Application.
Zeron-Medina J; Ochoa de Olza M; Braña I; Rodon J
Semin Oncol; 2015 Dec; 42(6):775-87. PubMed ID: 26615125
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
